Study design used by Emond et al. to identify DCTN4 as a genetic modifier for Cystic Fibrosis. In the first stage, the authors used and extreme design, followed by confirmation in a large second cohort of CF patients.

Ingo Helbig

Child Neurology Fellow and epilepsy genetics researcher at the Children’s Hospital of Philadelphia (CHOP), USA and Department of Neuropediatrics, Kiel, Germany

Facebook Twitter 

Leave a Reply

Your email address will not be published. Required fields are marked *